March 05, 2018

Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial

By Molly Parrish

In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.

Read the full article in The American of Tropical Medicine and Hygiene.

  • Commentary
    • August 3, 2020
    Institutional Roadblocks to the Defense Department’s Adoption of AI

    Bureaucratic inertia, stemming in part from deep-rooted institutional and cultural resistance, has hampered DoD’s ability to rapidly develop, acquire, and deploy AI capabiliti...

    By Megan Lamberth & Martijn Rasser

  • Commentary
    • Foreign Affairs
    • July 29, 2020
    Can China’s Military Win the Tech War?

    The United States and its allies should take seriously Beijing’s efforts to militarize China’s technological base....

    By Anja Manuel & Kathleen Hicks

  • Commentary
    • July 27, 2020
    Make China the Explicit Priority in the Next NDS

    The Bottom Line The new NDS is an opportunity for the next Secretary of Defense in January 2021 to do three things: Further deepen and explicitly state the current NDS’s sound...

    By Mark Montgomery & Eric Sayers

  • Commentary
    • July 23, 2020
    The Defense Industrial Base of the Future

    The next iteration of defense technologies will require much more overlap with commercial industry....

    By Mikhail Grinberg

View All Reports View All Articles & Multimedia